Summary RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases.The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy.
Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors.RegenxBio employs its proprietary NAV technology platform, a gene delivery technology to develop product candidates.
The company offers products for the treatment of metabolic, muscle, hematologic, ocular and neurodegenerative diseases and disorders.Its products also find application in the areas of gene therapy, gene modulation, protein therapeutics, genetic vaccines and protein screening.
RegenxBio is headquartered in Rockville, Maryland, the US.
RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth...
Glial Cell Line Derived Neurotrophic Factor - Drugs In Development, 2021 Summary According to the recently published report ’Glial Cell Line Derived Neurotrophic Factor - Drugs In Development, 2021’; Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target...
Tyrosine Protein Kinase Mer - Drugs In Development, 2021 Summary According to the recently published report ’Tyrosine Protein Kinase Mer - Drugs In Development, 2021’; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 18.104.22.168) pipeline Target constitutes...
C-C Chemokine Receptor Type 4 - Drugs In Development, 2021 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report...
This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as of July 2021. In vivo gene-encoded antibody delivery is an elegant approach to address many of the limitations of conventional therapeutic...
“Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant pleural mesothelioma (MPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by...
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 22.214.171.124) - Drugs In Development, 2021 Summary Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 126.96.36.199) - Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc., Quest Diagnostics, Thermo Fisher Scientific Inc., Pfizer, Bristol-Myers Squibb, Merck & Co. Inc., Tepnel Pharma Services, Abbott Laboratories, Takeda Pharmaceutical Company Ltd., and Eli Lilly and Company. The global precision medicine...
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
Retinoic Acid Receptor Alpha - Drugs In Development, 2021 Summary Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 15 molecules. The latest report Retinoic Acid Receptor Alpha - Drugs In Development, 2021,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.